Bluedrop Medical, headquartered in Galway and specialising in medical technology, has received a €1m equity injection from Enterprise Ireland according to an Irish Independent report.

The funding is aimed at supporting the company’s expansion into the US market and bolstering operational and R&D capacity in Ireland.

Founded in 2015 by Chris Murphy and Simon Kiersey, Bluedrop develops a remote patient-monitoring system that identifies diabetic foot ulcers early, helping prevent amputations. The system, comparable in form to a bathroom scale, captures high-definition images of patients’ feet which are then analysed using artificial intelligence and reviewed by experts.

Chris Murphy, co-founder and CEO, said: “For Bluedrop Medical, the funds will allow us to deliver our game-changing remote-monitoring system to more patients at risk of diabetic foot ulcers.” He added that the investment would support both US revenue growth and the building of operational and R&D capacity in Ireland over 2026 and beyond.

Bluedrop has previously raised €16m in funding, including a €10.5m round co-led by Atlantic Bridge and Elkstone in 2023, with additional backing from the European Innovation Council Fund, Furthr VC, and other syndicates. In 2024, the company aimed to raise up to €20m to support its next trial and commercial rollout in the US.

Enterprise Ireland’s new late-stage investment strategy aims to leverage larger funding rounds to attract more investors. The agency directly invested almost €50m in Irish companies in 2025, leveraging a total of €440m, and reported that 12,608 jobs were created across its backed firms that year.

Discover how Bluedrop Medical is shaping the future of diabetic foot care and driving medtech innovation in Ireland and abroad in the full article.